PharmSky Partners With Channel 10 on Peptide Story
PharmSky recently had the opportunity to work with Channel 10, providing analytical testing services to support their investigation into illegal […]
How the 2026/27 Australian Federal Budget Will Benefit the Emerging Biotech Industry
The Federal Budget announced last night has introduced several major reforms to the Australian R&D Tax Incentive (RDTI) program, creating
Meet us at Bio Korea 2026
PharmSky Research is heading to BIO-Korea! đź“ŤCoex, Seoulđź—“27 – 30 April Our Director of Business Development, Murali Nair, will be
PharmSky Awarded TGA GMP Manufacturing License — A Major Milestone in Our Growth as a Clinical Trial Partner
It’s Official – Good Manufacturing Practice (GMP) licensed We are incredibly proud to share that PharmSky has officially been granted
Regulatory Trends in Pharma Development: 2025 Outlook
Explore key regulatory trends shaping pharmaceutical development in 2025, including digital submissions, real-world evidence, and global harmonisation.
Navigating the World of Schedule 8 and 9 Substances
Medicines and chemicals are categorised into schedules based on their potential for abuse, medical use, and safety concerns. Among these
Discover our Extractables and Leachables (E&L) Testing Services
Regulators require drug product manufacturers to identify and quantify extractables and leachables so that their impact on patient safety and
